Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia.

Vanden Bempt M, Demeyer S, Broux M, De Bie J, Bornschein S, Mentens N, Vandepoel R, Geerdens E, Radaelli E, Bornhauser BC, Kulozik AE, Meijerink JP, Bourquin JP, de Bock CE, Cools J.

Cancer Cell. 2018 Aug 13;34(2):271-285.e7. doi: 10.1016/j.ccell.2018.07.007.

PMID:
30107177
2.

Malt1 self-cleavage is critical for regulatory T cell homeostasis and anti-tumor immunity in mice.

Baens M, Stirparo R, Lampi Y, Verbeke D, Vandepoel R, Cools J, Marynen P, de Bock CE, Bornschein S.

Eur J Immunol. 2018 Jul 19. doi: 10.1002/eji.201847597. [Epub ahead of print]

PMID:
30025160
3.

A comprehensive inventory of TLX1 controlled long non-coding RNAs in T-cell acute lymphoblastic leukemia through polyA+ and total RNA sequencing.

Verboom K, Van Loocke W, Volders PJ, Decaesteker B, Avila Cobos F, Bornschein S, de Bock CE, Kalender Atak Z, Clappier E, Aerts S, Cools J, Soulier J, Taghon T, Van Vlierberghe P, Vandesompele J, Speleman F, Durinck K.

Haematologica. 2018 Jun 28. pii: haematol.2018.190587. doi: 10.3324/haematol.2018.190587. [Epub ahead of print] No abstract available.

4.

HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development.

de Bock CE, Demeyer S, Degryse S, Verbeke D, Sweron B, Gielen O, Vandepoel R, Vicente C, Vanden Bempt M, Dagklis A, Geerdens E, Bornschein S, Gijsbers R, Soulier J, Meijerink JP, Heinäniemi M, Teppo S, Bouvy-Liivrand M, Lohi O, Radaelli E, Cools J.

Cancer Discov. 2018 May;8(5):616-631. doi: 10.1158/2159-8290.CD-17-0583. Epub 2018 Mar 1.

PMID:
29496663
5.

Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL.

Degryse S, Bornschein S, de Bock CE, Leroy E, Vanden Bempt M, Demeyer S, Jacobs K, Geerdens E, Gielen O, Soulier J, Harrison CJ, Constantinescu SN, Cools J.

Blood. 2018 Jan 25;131(4):421-425. doi: 10.1182/blood-2017-07-797597. Epub 2017 Nov 29.

6.

Defining the molecular basis of oncogenic cooperation between TAL1 expression and Pten deletion in T-ALL using a novel pro-T-cell model system.

Bornschein S, Demeyer S, Stirparo R, Gielen O, Vicente C, Geerdens E, Ghesquière B, Aerts S, Cools J, de Bock CE.

Leukemia. 2018 Apr;32(4):941-951. doi: 10.1038/leu.2017.328. Epub 2017 Nov 20.

7.

Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.

Degryse S, de Bock CE, Demeyer S, Govaerts I, Bornschein S, Verbeke D, Jacobs K, Binos S, Skerrett-Byrne DA, Murray HC, Verrills NM, Van Vlierberghe P, Cools J, Dun MD.

Leukemia. 2018 Mar;32(3):788-800. doi: 10.1038/leu.2017.276. Epub 2017 Aug 30.

8.

Adverse Events Following Vaccination With Bivalent rLP2086 (Trumenba®): An Observational, Longitudinal Study During a College Outbreak and a Systematic Review.

Fiorito TM, Baird GL, Alexander-Scott N, Bornschein S, Kelleher C, Du N, Dennehy PH.

Pediatr Infect Dis J. 2018 Jan;37(1):e13-e19. doi: 10.1097/INF.0000000000001742.

PMID:
28834957
9.

The T-cell leukemia-associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling.

Girardi T, Vereecke S, Sulima SO, Khan Y, Fancello L, Briggs JW, Schwab C, de Beeck JO, Verbeeck J, Royaert J, Geerdens E, Vicente C, Bornschein S, Harrison CJ, Meijerink JP, Cools J, Dinman JD, Kampen KR, De Keersmaecker K.

Leukemia. 2018 Mar;32(3):809-819. doi: 10.1038/leu.2017.225. Epub 2017 Jul 24.

10.

Rapid response to a college outbreak of meningococcal serogroup B disease: Nation's first widespread use of bivalent rLP2086 vaccine.

Fiorito TM, Bornschein S, Mihalakos A, Kelleher CM, Alexander-Scott N, Kanadanian KV, Raymond P, Sicard K, Dennehy PH.

J Am Coll Health. 2017 May-Jun;65(4):294-296. doi: 10.1080/07448481.2017.1285772. Epub 2017 Jan 25.

PMID:
28121236
11.

IL-2 consumption by highly activated CD8 T cells induces regulatory T-cell dysfunction in patients with hemophagocytic lymphohistiocytosis.

Humblet-Baron S, Franckaert D, Dooley J, Bornschein S, Cauwe B, Schönefeldt S, Bossuyt X, Matthys P, Baron F, Wouters C, Liston A.

J Allergy Clin Immunol. 2016 Jul;138(1):200-209.e8. doi: 10.1016/j.jaci.2015.12.1314. Epub 2016 Mar 4.

12.

Brief Report: IFIH1 Mutation Causes Systemic Lupus Erythematosus With Selective IgA Deficiency.

Van Eyck L, De Somer L, Pombal D, Bornschein S, Frans G, Humblet-Baron S, Moens L, de Zegher F, Bossuyt X, Wouters C, Liston A.

Arthritis Rheumatol. 2015 Jun;67(6):1592-7. doi: 10.1002/art.39110.

13.

The intracellular sensor NOD2 induces microRNA-29 expression in human dendritic cells to limit IL-23 release.

Brain O, Owens BM, Pichulik T, Allan P, Khatamzas E, Leslie A, Steevels T, Sharma S, Mayer A, Catuneanu AM, Morton V, Sun MY, Jewell D, Coccia M, Harrison O, Maloy K, Schönefeldt S, Bornschein S, Liston A, Simmons A.

Immunity. 2013 Sep 19;39(3):521-36. doi: 10.1016/j.immuni.2013.08.035.

14.

Patient-doctor interaction, psychobehavioural characteristics and mental disorders in patients with suspected allergies: do they predict "medically unexplained symptoms"?

Hausteiner-Wiehle C, Grosber M, Bubel E, Groben S, Bornschein S, Lahmann C, Eyer F, Eberlein B, Behrendt H, Löwe B, Henningsen P, Huber D, Ring J, Darsow U.

Acta Derm Venereol. 2011 Oct;91(6):666-73. doi: 10.2340/00015555-1147.

15.

Cognitive decline in the behavioral variant of frontotemporal dementia.

Diehl-Schmid J, Bornschein S, Pohl C, Förstl H, Kurz A, Jahn T.

Int Psychogeriatr. 2011 Mar;23(2):230-7. doi: 10.1017/S104161021000164X. Epub 2010 Sep 14.

PMID:
20836915
16.

Characteristics of oligosymptomatic versus polysymptomatic presentations of somatoform disorders in patients with suspected allergies.

Hausteiner C, Huber D, Bornschein S, Grosber M, Bubel E, Groben S, Lahmann C, Löwe B, Eyer F, Eberlein B, Ring J, Behrendt H, Darsow U, Henningsen P.

J Psychosom Res. 2010 Sep;69(3):259-66. doi: 10.1016/j.jpsychores.2010.03.006.

PMID:
20708448
17.

Predictors of treatment outcomes after removal of amalgam fillings: associations between subjective symptoms, psychometric variables and mercury levels.

Weidenhammer W, Bornschein S, Zilker T, Eyer F, Melchart D, Hausteiner C.

Community Dent Oral Epidemiol. 2010 Apr;38(2):180-9. doi: 10.1111/j.1600-0528.2009.00523.x. Epub 2010 Jan 14.

PMID:
20074291
18.

Psychobehavioral predictors of somatoform disorders in patients with suspected allergies.

Hausteiner C, Bornschein S, Bubel E, Groben S, Lahmann C, Grosber M, Löwe B, Eyer F, Eberlein B, Behrendt H, Darsow U, Ring J, Henningsen P, Huber D.

Psychosom Med. 2009 Nov;71(9):1004-11. doi: 10.1097/PSY.0b013e3181b4fe3a. Epub 2009 Aug 6.

PMID:
19661185
19.

Does a specific dental amalgam syndrome exist? A comparative study.

Weidenhammer W, Hausteiner C, Zilker T, Melchart D, Bornschein S.

Acta Odontol Scand. 2009;67(4):233-9. doi: 10.1080/00016350902915348.

PMID:
19391051
20.

Accelerated clinical decline in well-educated patients with frontotemporal lobar degenerations.

Perneczky R, Pohl C, Bornschein S, Förstl H, Kurz A, Diehl-Schmid J.

Eur Arch Psychiatry Clin Neurosci. 2009 Sep;259(6):362-7. doi: 10.1007/s00406-009-0004-6. Epub 2009 Mar 3.

PMID:
19255708
21.

Double-blind placebo-controlled provocation study in patients with subjective Multiple Chemical Sensitivity (MCS) and matched control subjects.

Bornschein S, Hausteiner C, Römmelt H, Nowak D, Förstl H, Zilker T.

Clin Toxicol (Phila). 2008 Jun;46(5):443-9. doi: 10.1080/15563650701742438.

PMID:
18568800
22.

Pest controllers: a high-risk group for Multiple Chemical Sensitivity (MCS)?

Bornschein S, Hausteiner C, Pohl C, Jahn T, Angerer J, Foerstl H, Zilker T.

Clin Toxicol (Phila). 2008 Mar;46(3):193-200. doi: 10.1080/15563650601185126.

PMID:
18344101
23.

Neuropsychological and positron emission tomography correlates in idiopathic environmental intolerances.

Bornschein S, Hausteiner C, Drzezga A, Theml T, Heldmann B, Grimmer T, Perneczky R, Jahn T, Schwaiger M, Zilker T, Förstl H.

Scand J Work Environ Health. 2007 Dec;33(6):447-53.

24.

Dysfunctional cognitions in idiopathic environmental intolerances (IEI)--an integrative psychiatric perspective.

Hausteiner C, Bornschein S, Zilker T, Henningsen P, Förstl H.

Toxicol Lett. 2007 Jun 15;171(1-2):1-9. Epub 2007 May 1. Review.

PMID:
17548174
25.

[The influence of diet on mental health].

Hausteiner C, Bornschein S, Zilker T, Förstl H, Grassmann J.

Nervenarzt. 2007 Jun;78(6):696, 698-700, 702-5. Review. German.

PMID:
17457560
26.

[Working hours and job satisfaction among physicians in hospitals and general practice in Munich. Results of an anonymous questionnaire].

Bornschein S, Erbas B, Borelli S, Emminger C, Hesse J, Pilz J, Schwarzkopf-Steinhauser G, Wenzl H, Kunze D, Borelli C.

Gesundheitswesen. 2006 Aug-Sep;68(8-9):535-44. German.

PMID:
17039432
27.

Longitudinal changes of cerebral glucose metabolism in semantic dementia.

Diehl-Schmid J, Grimmer T, Drzezga A, Bornschein S, Perneczky R, Forstl H, Schwaiger M, Kurz A.

Dement Geriatr Cogn Disord. 2006;22(4):346-51. Epub 2006 Sep 4.

PMID:
16954690
28.

Psychiatric morbidity and toxic burden in patients with environmental illness: a controlled study.

Bornschein S, Hausteiner C, Konrad F, Förstl H, Zilker T.

Psychosom Med. 2006 Jan-Feb;68(1):104-9.

PMID:
16449419
29.

Decline of cerebral glucose metabolism in frontotemporal dementia: a longitudinal 18F-FDG-PET-study.

Diehl-Schmid J, Grimmer T, Drzezga A, Bornschein S, Riemenschneider M, Förstl H, Schwaiger M, Kurz A.

Neurobiol Aging. 2007 Jan;28(1):42-50. Epub 2006 Jan 31.

PMID:
16448722
30.

New aspects of psychiatric morbidity in idiopathic environmental intolerances.

Hausteiner C, Mergeay A, Bornschein S, Zilker T, Förstl H.

J Occup Environ Med. 2006 Jan;48(1):76-82.

PMID:
16404213
31.

Self-reported chemical sensitivity in Germany: a population-based survey.

Hausteiner C, Bornschein S, Hansen J, Zilker T, Förstl H.

Int J Hyg Environ Health. 2005;208(4):271-8.

PMID:
16078641
32.

[Multiple chemical sensitivity. Is the patient suffering as a result of environmental pollutants or psychological problems?].

Hausteiner C, Bornschein S, Förstl H, Zilker T.

MMW Fortschr Med. 2003 Aug 21;145(33-34):31-4. German.

PMID:
14526571
33.

Psychiatric morbidity and low self-attentiveness in patients with environmental illness.

Hausteiner C, Bornschein S, Bickel H, Zilker T, Forstl H.

J Nerv Ment Dis. 2003 Jan;191(1):50-5.

PMID:
12544600
34.

PET in patients with clear-cut multiple chemical sensitivity (MCS).

Bornschein S, Hausteiner C, Drzezga A, Bartenstein P, Schwaiger M, Förstl H, Zilker T.

Nuklearmedizin. 2002 Dec;41(6):233-9.

PMID:
12520659
35.

[Psychiatric aspects of multiple chemical sensitivity (MCS)].

Bornschein S, Hausteiner C, Förstl H, Zilker T.

Versicherungsmedizin. 2002 Dec 1;54(4):163-7. German.

PMID:
12491564
36.

Psychiatric and somatic disorders and multiple chemical sensitivity (MCS) in 264 'environmental patients'.

Bornschein S, Hausteiner C, Zilker T, Förstl H.

Psychol Med. 2002 Nov;32(8):1387-94.

PMID:
12455937
37.

Idiopathic environmental intolerances (formerly multiple chemical sensitivity) psychiatric perspectives.

Bornschein S, Förstl H, Zilker T.

J Intern Med. 2001 Oct;250(4):309-21. Review.

38.

[Psychiatric and somatic morbidity of patients with suspected multiple chemical sensitivity syndrome (MCS)].

Bornschein S, Hausteiner C, Zilker T, Bickel H, Förstl H.

Nervenarzt. 2000 Sep;71(9):737-44. German.

PMID:
11042869

Supplemental Content

Loading ...
Support Center